FOR SAFER, MORE EFFICIACIOUS AND ACCESSIBLE AAV GENE THERAPY
Our vision is to innovate AAV bioproduction and provide a platform aimed at order of magnitudes improvement compared to state-of-art today. We do this by combining expertise from experts of different areas aligning world-leading Swedish faculty within cellbiology, pharmacology, systems biology, neurology, drug discovery, industrial biotechnology, and mathematics with Swedish global commercial technology, service providers and biopharmaceutical companies to one goal – to enable the sustainable access to curative treatment by AAV for the patient. GeneNova is funded by partner companies and VINNOVA Sweden’s innovation agency 2021-2026.
Coordinator: KTH Royal Inst Technology.
Partners: Alfa Laval, AstraZeneca, Biotage, Combigene, Karolinska Institutet, Uppsala University, Vironova, Ziccum
- Automation of plasmid preparation
- Vector engineering
- Cell line engineering
- Bioprocess engineering
- Gentle separation
- Downstream purification
- Gentle formulation
- In vitro and in vivo PoC
- Machine learning for improved HTP
- Electron Microscopy and NGS sequencing
Contact: Johan Rockberg
Opportunities and challenges for Sweden to become internationally leading in the field of gene therapy,